VistaGen Therapeutics, Inc. (Vistagen) is a biotechnology company engaged in the human pluripotent stem cell technology (hPSC technology). The Company is applying its hPSC technology for drug rescue, predictive toxicology and drug metabolism screening. The Companys products include CardioSafe 3D, LiverSafe 3D and AV-101. The Company has developed CardioSafe 3D, a three-dimensional (3D) in vitro bioassay system for predicting in vivo cardiac effects, both toxic and non-toxic, of small molecule drug candidates long before they are tested in animals or humans. With its mature human liver cells derived from pluripotent stem cells, the Company is developing and validating LiverSafe 3D, a three-dimensional (3D) in vitro bioassay system for assessing liver toxicity and drug metabolism issues. AV-101 is its orally available small molecule prodrug candidate aimed at the multi-billion dollar neurological disease and disorders market.
